Does TILDRAKIZUMAB Cause Nasopharyngitis? 8 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Nasopharyngitis have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 0.9% of all adverse event reports for TILDRAKIZUMAB.
8
Reports of Nasopharyngitis with TILDRAKIZUMAB
0.9%
of all TILDRAKIZUMAB reports
1
Deaths
1
Hospitalizations
How Dangerous Is Nasopharyngitis From TILDRAKIZUMAB?
Of the 8 reports, 1 (12.5%) resulted in death, 1 (12.5%) required hospitalization.
Is Nasopharyngitis Listed in the Official Label?
Yes, Nasopharyngitis is listed as a known adverse reaction in the official FDA drug label for TILDRAKIZUMAB.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Product dose omission issue (53)
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Off label use (27)
Condition aggravated (25)
Covid-19 (25)
Inappropriate schedule of product administration (22)
What Other Drugs Cause Nasopharyngitis?
ADALIMUMAB (13,753)
ETANERCEPT (12,421)
METHOTREXATE (8,046)
TOFACITINIB (7,781)
SECUKINUMAB (7,022)
TOCILIZUMAB (6,664)
RITUXIMAB (6,321)
ABATACEPT (6,143)
INFLIXIMAB (5,353)
CERTOLIZUMAB PEGOL (5,295)
Which TILDRAKIZUMAB Alternatives Have Lower Nasopharyngitis Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE